JPWO2020257671A5 - - Google Patents

Download PDF

Info

Publication number
JPWO2020257671A5
JPWO2020257671A5 JP2021575387A JP2021575387A JPWO2020257671A5 JP WO2020257671 A5 JPWO2020257671 A5 JP WO2020257671A5 JP 2021575387 A JP2021575387 A JP 2021575387A JP 2021575387 A JP2021575387 A JP 2021575387A JP WO2020257671 A5 JPWO2020257671 A5 JP WO2020257671A5
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
administered
azacytidine
therapeutic agent
additional therapeutic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2021575387A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022537551A (ja
Publication date
Application filed filed Critical
Priority claimed from PCT/US2020/038772 external-priority patent/WO2020257671A1/en
Publication of JP2022537551A publication Critical patent/JP2022537551A/ja
Publication of JPWO2020257671A5 publication Critical patent/JPWO2020257671A5/ja
Pending legal-status Critical Current

Links

JP2021575387A 2019-06-20 2020-06-19 ベネトクラクス、ギルテリチニブ、ミドスタウリン、または白血病もしくは骨髄異形成症候群を治療するための他の化合物との組み合わせにおけるアザシチジン Pending JP2022537551A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962864413P 2019-06-20 2019-06-20
US62/864,413 2019-06-20
PCT/US2020/038772 WO2020257671A1 (en) 2019-06-20 2020-06-19 Azacitidine in combination with venetoclax, gilteritinib, midostaurin or other compounds for treating leukemia or myelodysplastic syndrome

Publications (2)

Publication Number Publication Date
JP2022537551A JP2022537551A (ja) 2022-08-26
JPWO2020257671A5 true JPWO2020257671A5 (enExample) 2023-06-08

Family

ID=71528047

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2021575509A Pending JP2022537384A (ja) 2019-06-20 2020-06-19 ベネトクラクス、ギルテリチニブ、ミドスタウリン、または白血病もしくは骨髄異形成症候群を治療するための他の化合物との組み合わせにおけるアザシチジン
JP2021575387A Pending JP2022537551A (ja) 2019-06-20 2020-06-19 ベネトクラクス、ギルテリチニブ、ミドスタウリン、または白血病もしくは骨髄異形成症候群を治療するための他の化合物との組み合わせにおけるアザシチジン

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP2021575509A Pending JP2022537384A (ja) 2019-06-20 2020-06-19 ベネトクラクス、ギルテリチニブ、ミドスタウリン、または白血病もしくは骨髄異形成症候群を治療するための他の化合物との組み合わせにおけるアザシチジン

Country Status (11)

Country Link
US (2) US20220249528A1 (enExample)
EP (2) EP3986403A1 (enExample)
JP (2) JP2022537384A (enExample)
KR (2) KR20220050874A (enExample)
CN (2) CN115066243A (enExample)
AU (2) AU2020296179A1 (enExample)
BR (2) BR112021025537A2 (enExample)
CA (2) CA3143711A1 (enExample)
IL (2) IL289110A (enExample)
MX (2) MX2021015993A (enExample)
WO (2) WO2020257665A1 (enExample)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3597741A1 (en) 2012-04-27 2020-01-22 Duke University Genetic correction of mutated genes
US9828582B2 (en) 2013-03-19 2017-11-28 Duke University Compositions and methods for the induction and tuning of gene expression
JP6929791B2 (ja) 2015-02-09 2021-09-01 デューク ユニバーシティ エピゲノム編集のための組成物および方法
US11970710B2 (en) 2015-10-13 2024-04-30 Duke University Genome engineering with Type I CRISPR systems in eukaryotic cells
KR102787119B1 (ko) 2015-11-30 2025-03-27 듀크 유니버시티 유전자 편집에 의한 인간 디스트로핀 유전자의 교정을 위한 치료용 표적 및 사용 방법
US20190127713A1 (en) 2016-04-13 2019-05-02 Duke University Crispr/cas9-based repressors for silencing gene targets in vivo and methods of use
EP4275747A3 (en) 2016-07-19 2024-01-24 Duke University Therapeutic applications of cpf1-based genome editing
US12509492B2 (en) 2018-01-19 2025-12-30 Duke University Genome engineering with CRISPR-Cas systems in eukaryotes
WO2022187288A2 (en) * 2021-03-01 2022-09-09 Duke University Systems and methods for genome-wide annotation of gene regulatory elements linked to cell fitness
WO2022215995A1 (ko) * 2021-04-05 2022-10-13 주식회사 피노바이오 4'-티오-5-아자-2'-디옥시사이티딘 및 베네토클락스의 병용 요법
CN117651556A (zh) * 2021-05-11 2024-03-05 艾伯维公司 与cyp3a抑制剂和阿扎胞苷联合治疗骨髓增生异常综合征的维奈托克给药方案
CA3219760A1 (en) * 2021-05-11 2022-11-17 Abbvie Inc. Venetoclax dosing regimens for use in treating myelodysplastic syndromes in combination with azacitidine
US20250312327A1 (en) * 2021-10-14 2025-10-09 Pharos Ibio Co., Ltd Composition for combination therapy, comprising 2,3,5-substituted thiophene compound
JP2025502748A (ja) 2021-12-30 2025-01-28 バイオメア フュージョン，インコーポレイテッド Ｆｌｔ３の阻害剤としてのピラジン化合物
EP4544051A2 (en) 2022-06-24 2025-04-30 Tune Therapeutics, Inc. Compositions, systems, and methods for reducing low-density lipoprotein through targeted gene repression

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2774226T3 (es) * 2008-05-15 2020-07-17 Celgene Corp Formulaciones orales de análogos de citidina y métodos de uso de los mismos
PE20161438A1 (es) 2014-05-01 2017-01-18 Celgene Quanticel Res Inc Inhibidores de desmetilasa 1 especifica a lisina
EP3189038B1 (en) 2014-09-05 2022-11-23 Celgene Quanticel Research, Inc. Inhibitors of lysine specific demethylase-1
CN106604745A (zh) 2014-09-08 2017-04-26 细胞基因公司 使用胞苷类似物的口服制剂与抗pd1或抗pdl1单克隆抗体的组合治疗疾病或病症的方法
CA3002029A1 (en) 2015-10-15 2017-04-20 Celgene Corporation Combination therapy for treating malignancies
ES2897959T3 (es) 2015-10-15 2022-03-03 Servier Lab Terapia de combinación para tratar neoplasias malignas
ES2846951T3 (es) 2015-11-05 2021-07-30 Celgene Quanticel Res Inc Composiciones que comprenden un inhibidor de desmetilasa-1 específica para lisina, que tiene un anillo de pirimidina, y su uso en el tratamiento del cáncer
MX2018011100A (es) 2016-03-15 2019-01-10 Oryzon Genomics Sa Combinaciones de inhibidores de desmetilasa-1 especifica de lisina (lsd1) para el tratamiento de malignidades hematologicas.
US20200069677A1 (en) 2016-12-09 2020-03-05 Constellation Pharmaceuticals, Inc. Markers for personalized cancer treatment with lsd1 inhibitors
EP3644999B1 (en) 2017-06-30 2022-12-14 Celgene Corporation Compositions and methods of use of 2-(4-chlorophenyl)-n-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl) methyl) -2,2-difluoroacetamide
IL271946B (en) 2017-07-09 2022-09-01 Biosight Ltd Combination cancer therapy
TWI848030B (zh) 2018-12-18 2024-07-11 比利時商阿根思公司 Ｃｄ７０組合治療

Similar Documents

Publication Publication Date Title
JP2022009090A5 (enExample)
JP2023002662A5 (enExample)
JPWO2020257671A5 (enExample)
JP2023041862A5 (enExample)
JP2020073546A5 (enExample)
JP2023088944A5 (enExample)
JP2024133474A5 (enExample)
JP2019503365A5 (enExample)
JP2014526503A5 (enExample)
JP2021509395A5 (enExample)
CN109985237B (zh) 一种治疗结直肠癌的药物组合物及其应用
JP2015517523A5 (enExample)
JP2016507500A5 (enExample)
JP2024016209A5 (enExample)
JP2019218379A5 (enExample)
JPWO2019241442A5 (enExample)
JP2020515523A5 (enExample)
JPWO2020257665A5 (enExample)
JP2016505050A5 (enExample)
JPWO2022182857A5 (enExample)
JP2022177119A5 (enExample)
CN101357134A (zh) 抗肿瘤效果增强剂和抗肿瘤剂
JP2025148408A5 (enExample)
US11628163B2 (en) 1-piperidinepropionic acid for treating a fibrosing disease
MX2024006270A (es) Nueva composicion farmaceutica oral y regimen de dosificacion para la terapia de enfermedades pulmonares intersticiales fibrosantes progresivas.